期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

吉非替尼治疗晚期NSCLC 3例临床观察并文献复习

下载PDF
导出
摘要 目的通过对吉非替尼(Iressa ZD1839)治疗的3例晚期NSCLC病人的观察及文献复习，进一步了解Iressa的临床治疗价值。方法对经病理确诊的2例化疗无效及1例因其它疾病不能接受化疗的NSCLC病人给予每日口服Iressa250mg，并随访至2004年11月30日。结果2例分别服药至第3、4天症状出现改善，1例18天、1例21天做胸CT复查，双肺弥漫性转移病灶均明显减少。其中1例缓解5个月后病情进展，1例缓解9个月(目前)仍稳定。另1例服药37天无效，病情进展并出现严重腹泻被迫停药，第40天死亡。结论通过3例观察并结合文献报道，Iressa口服方便，毒性小，起效快，对无论是初治还是复治的晚期和转移NSCLC有一定疗效。提高了部分患者的生存期和生活质量。
作者 胡培安 孙怡芬 仝丽 李宝兰 傅瑜
机构地区 北京胸部肿瘤结核病医院
出处 《结核病与胸部肿瘤》 2005年第2期101-106,共6页 Tuberculosis and Thoracic Tumor
关键词 吉非替尼 药物治疗 非小细胞肺癌 帕米磷酸二钠 静脉给药
分类号 R734.2 [医药卫生—肿瘤] R979.1 [医药卫生—药品]
  • 相关文献

参考文献16

  • 1Muthuswamy SK,Gilman M,Brugge JS . Controlled dimerization of ErbB receptors provides evidence for Differential Signaling by homo and heterodimers . Mol Cell Biol,1999,19(10) :6845-6857.
  • 2Datta SR,Dudek H,Tao X,et al.Akt phosphorylation of BAD couples survival signals to the cell-intrinsic Death machinery.Cell,1997,91 (2) :231-241.
  • 3Cardone MH,Roy N,Stennicke HR,et al. Regulation of cell death protease caspase-9 by phosphorylation.Science, 1998,282(5392) : 1318-1321.
  • 4Iardiello F,Caputo R,Bianco R,et al. Inhibition of growth factor production and angiogenesis in humal cancer Cells by ZD1839(Iressa),a selective epidermal growth factor receptor tyrosine kinase inhibitor . Clin Cancer Res, 2001,7(5) : 1459-1465.
  • 5Herbst RS,Maddox AM,Rothenberg ML,et al.Selective oral epidermal growth factor receptor tyrosine kinase Inhibitor ZD1839 is generally weB-tolerated and has activity in non-small-cell lung cancer and other solid tumors:relults of a phase Ⅰ Trial . J Clin Oncol,2002,20(18) :3815-3825.
  • 6Fukuoka M,Yano S, Giaccone G, et al. Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol,2003,21(12):2237-2246.
  • 7Lorusso PM, Herbst RS, Rischin D,et al. Improvements in Quality of Life and Ddisease-related Symptoms in Phase Ⅰ Trials of the Selective Oral Epidermal Growth Factor Tyrosine Kinase Inhibitor ZD1839 in Non-small Cell Lung Cancer and Other Solid Tumors. Clin Cancer Res,2003,9(6):2040-2048.
  • 8Schiller JH . New directions for ZD1839 in the treatment of solid tumors . Semin Oncol, 2003, 30(1 Suppl 1):49-55.
  • 9Herbst RS.Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients. Semin Oncol, 2003, 30(1 Suppl 1):30-38.
  • 10Baselga J,Rischin D,Ranson M,et al. Phase Ⅰ safety,pharmacokinetic,and pharmacodynamic trial of ZD1839,a selective oral epidermal growth factor receptor tyrosine kinase inhibitor,in patients with five selected solid tumor types . J Clin Oncol, 2002,20(21):4292-4302.

二级参考文献61

  • 1Jemal,A,Murray T,Samuels,et al,Cancer statistics,2003[J].CA Cancer J Clin,2004,53:5-6.
  • 2Parkin DM,Bray FI,Devesa SS.Cancer burden in the year 2000.The global picture[J].Eur J Cancer,2001,37:S4-S66.
  • 3Bunn PA.Treatment of advanced non-small-cell lung cancer with two drug combinations [J].J Clin Oncol,2002,20:3565-3567.
  • 4Schmidt M,Maurer-gebhard M,Groner B,et al.Suppression of metastasis formation by a recombinant single chain antibody toxin targeted to full length and oncogenic variant EGF reeeptors[J].Oncogene,1999,18:1711-1721.
  • 5Ciardiello F,Caputo R,Bianco R,et al.Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839(iressa),a selective epidermal growth factor receptor tyrosine kinase inhibitor[J].Clin Cancer Res,2001,7:1459-1465.
  • 6Fukuoka M,Yano S,Giaccone G,et al.Multi-institutional phase Ⅱ trial of gefitinib for previously treated patients with advance non-small-cell lung cancer[J].J Clin Oncol,2003,21:2237-2246.
  • 7Prenzel N,Fischer OM,Streit S,et al.The epidermal growth factor receptors:critical mediators of multiple receptor pathways[J].Curr Opin Cell Biol,1999,Ⅱ:184-189.
  • 8Nicholson RI,Gec JM,Harper ME.EGFR and cancer prognosis[J].Eur J Cancer,2001,37(Suppl 4):S9-15.
  • 9Baselga J,Rischin D,Ranson M,et al.Phase Ⅰ safety,pharmacokinetic,and pharmaeodynamic trial of ZD1839,a selective oral epidermal growth factor receptor tyrosine kinase inhibitor,in patients with five selected solid tumor types[J].J Clin Oncol,2002,20(21):4292-4302.
  • 10Herbst RS, Maddox AM, Rothenberg ML, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase Ⅰ trial. J

共引文献66

结核病与胸部肿瘤
2005年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部